Good Clinical Approach: Delphi Consensus for the Use of Betahistine in Menière’s Disease

Table 2

Results of the Consensus Conference on the use and dosage of betahistine during the acute attacks of MD. 1 = absolutely disagree, 2 = disagree, 3 = agree, 4 = more than agree, and 5 = absolutely agree. Consensus was reached when the sum of items 1 and 2 or 3, 4, and 5 reached 66%. Same asterisk convention.

During an attack, referred to the vertigo in the Menière’s disease do you think that betahistine:
1. Is the first-choice drug in monotherapy	47%	27%	16%	5%	5%
	74		26
2. Is useful when associated to other therapies	14%	14%	47%	23%	2%
	28		72
3. Is not useful	17%	17%	46%	3%	17%
	34		66
4. Shows poor efficacy	9%	3%	48%	9%	31%
	12		88
If you use Betahistine during acute attacks, what is the dosage?
1. I do not use betahistine during acute attacks	10 %	17 %	34 %	19 %	20 %
	27		73
2. Range from 8 to 32 mg/day	44 %	43 %	13 %	0 %	0 %
	87		13
3. Range from 32 to 48 mg/day	19 %	28 %	38 %	9 %	6 %
	47		53
4. Higher than 48 mg/day	30 %	20 %	34 %	13 %	3 %
	50		50